These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31526003)

  • 1. Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine D
    Shaik AB; Kumar V; Bonifazi A; Guerrero AM; Cemaj SL; Gadiano A; Lam J; Xi ZX; Rais R; Slusher BS; Newman AH
    J Med Chem; 2019 Oct; 62(20):9061-9077. PubMed ID: 31526003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
    Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH
    J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly D
    Galaj E; Bi GH; Klein B; Hempel B; Shaik AB; Gogarnoiu ES; Friedman J; Lam J; Rais R; Reed JF; Bloom SH; Swanson TL; Schmachtenberg JL; Eshleman AJ; Janowsky A; Xi ZX; Newman AH
    Neuropsychopharmacology; 2022 Dec; 47(13):2309-2318. PubMed ID: 35879349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D
    Kumar V; Moritz AE; Keck TM; Bonifazi A; Ellenberger MP; Sibley CD; Free RB; Shi L; Lane JR; Sibley DR; Newman AH
    J Med Chem; 2017 Feb; 60(4):1478-1494. PubMed ID: 28186762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.
    Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML
    Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Perspectives on Selective Dopamine D
    Newman AH; Xi ZX; Heidbreder C
    Curr Top Behav Neurosci; 2023; 60():157-201. PubMed ID: 35543868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
    Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
    ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.
    Newman AH; Blaylock BL; Nader MA; Bergman J; Sibley DR; Skolnick P
    Biochem Pharmacol; 2012 Oct; 84(7):882-90. PubMed ID: 22781742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine D
    Battiti FO; Zaidi SA; Katritch V; Newman AH; Bonifazi A
    J Med Chem; 2021 Nov; 64(21):16088-16105. PubMed ID: 34699207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D
    Moritz AE; Bonifazi A; Guerrero AM; Kumar V; Free RB; Lane JR; Verma RK; Shi L; Newman AH; Sibley DR
    ACS Chem Neurosci; 2020 Oct; 11(20):3309-3320. PubMed ID: 32969645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly Developed Dopamine D
    Jordan CJ; Humburg BA; Thorndike EB; Shaik AB; Xi ZX; Baumann MH; Newman AH; Schindler CW
    J Pharmacol Exp Ther; 2019 Dec; 371(3):602-614. PubMed ID: 31562201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists.
    Choi JK; Mandeville JB; Chen YI; Grundt P; Sarkar SK; Newman AH; Jenkins BG
    Psychopharmacology (Berl); 2010 Sep; 212(1):59-72. PubMed ID: 20628733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice.
    Boateng CA; Bakare OM; Zhan J; Banala AK; Burzynski C; Pommier E; Keck TM; Donthamsetti P; Javitch JA; Rais R; Slusher BS; Xi ZX; Newman AH
    J Med Chem; 2015 Aug; 58(15):6195-213. PubMed ID: 26203768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y; Min C; Acharya S; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Dual-Target μ-Opioid Receptor and Dopamine D
    Bonifazi A; Battiti FO; Sanchez J; Zaidi SA; Bow E; Makarova M; Cao J; Shaik AB; Sulima A; Rice KC; Katritch V; Canals M; Lane JR; Newman AH
    J Med Chem; 2021 Jun; 64(11):7778-7808. PubMed ID: 34011153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current drug treatments targeting dopamine D3 receptor.
    Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
    Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H
    Biselli S; Bresinsky M; Tropmann K; Forster L; Honisch C; Buschauer A; Bernhardt G; Pockes S
    Eur J Med Chem; 2021 Mar; 214():113190. PubMed ID: 33548637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.